Mechanisms Underlying Food-Triggered Symptoms in Disorders of Gut-Brain Interactions.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
14
01
2022
accepted:
26
04
2022
pubmed:
5
5
2022
medline:
9
6
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
There has been a dramatic increase in clinical studies examining the relationship between disorders of gut-brain interactions and symptoms evoked by food ingestion in the upper and lower gastrointestinal tract, but study design is challenging to verify valid endpoints. Consequently, mechanistic studies demonstrating biological relevance, biomarkers and novel therapeutic targets are greatly needed. This review highlights emerging mechanisms related to nutrient sensing and tasting, maldigestion, physical effects with underlying visceral hypersensitivity, allergy and immune mechanisms, food-microbiota interactions and gut-brain signaling, with a focus on patients with functional dyspepsia and irritable bowel syndrome. Many patients suffering from disorders of gut-brain interactions exhibit these mechanism(s) but which ones and which specific properties may vary widely from patient to patient. Thus, in addition to identifying these mechanisms and the need for further studies, biomarkers and novel therapeutic targets are identified that could enable enriched patient groups to be studied in future clinical trials examining the role of food in the generation of gut and non-gut symptoms.
Identifiants
pubmed: 35506862
doi: 10.14309/ajg.0000000000001812
pii: 00000434-202206000-00026
pmc: PMC9169752
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
937-946Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Farré R, Tack J. Food and symptom generation in functional gastrointestinal disorders: Physiological aspects. Am J Gastroenterol 2013;108:698–706.
Sun WM, Houghton LA, Read NW, et al. Effect of meal temperature on gastric emptying of liquids in man. Gut 1988;29:302–5.
Powley TL, Phillips RJ. Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav 2004;82:69–74.
Piessevaux H, Tack J, Wilmer A, et al. Perception of changes in wall tension of the proximal stomach in humans. Gut 2001;49:203–8.
Corsetti M, Gevers AM, Caenepeel P, et al. The role of tension receptors in colonic mechanosensitivity in humans. Gut 2004;53:1787–93.
Murray K, Wilkinson-Smith V, Hoad C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2014;109:110–9.
Burman A, Kaji I. Luminal chemosensory cells in the small intestine. Nutrients 2021;13:3712.
Yang M, Reimann F, Gribble FM. Chemosensing in enteroendocrine cells: Mechanisms and therapeutic opportunities. Curr Opin Endocrinol Diabetes Obes 2021;28:222–31.
Boesmans W, Owsianik G, Tack J, et al. TRP channels in neurogastroenterology: Opportunities for therapeutic intervention. Br J Pharmacol 2011;162:18–37.
Depoortere I. Taste receptors of the gut: Emerging roles in health and disease. Gut 2014;63:179–90.
Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 1995;7:1051–7.
Demarchi B, Vos R, Deprez P, et al. Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal. Aliment Pharmacol Ther 2004;19:1261–8.
Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001;48:347–55.
Van den Houte K, Scarpellini E, Verbeure W, et al. The role of GI peptides in functional dyspepsia and gastroparesis: A systematic review. Front Psychiatry 2020;11:172.
Bharucha AE, Camilleri M, Burton DD, et al. Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 2014;109:1910–20; quiz 1909, 1921.
Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349–57.
Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34–43.
Hammer J, Führer M, Pipal L, et al. Hypersensitivity for capsaicin in patients with functional dyspepsia. Neurogastroenterol Motil 2008;20:125–33.
Tack J, Verbeure W, Mori H, et al. The gastrointestinal tract in hunger and satiety signalling. United European Gastroenterol J 2021;9:727–34.
Verbeure W, Deloose E, Tóth J, et al. The endocrine effects of bitter tastant administration in the gastrointestinal system: Intragastric versus intraduodenal administration. Am J Physiol Endocrinol Metab 2021;321:E1–e10.
Meyer-Gerspach AC, Biesiekierski JR, Deloose E, et al. Effects of caloric and noncaloric sweeteners on antroduodenal motility, gastrointestinal hormone secretion and appetite-related sensations in healthy subjects. Am J Clin Nutr 2018;107:707–16.
Meyer-Gerspach AC, Drewe J, Verbeure W, et al. Effect of the natural sweetener xylitol on gut hormone secretion and gastric emptying in humans: A pilot dose-ranging study. Nutrients 2021;13:3950.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:262–8.e1.
Algera J, Colomier E, Simrén M. The dietary management of patients with irritable bowel syndrome: A narrative review of the existing and emerging evidence. Nutrients 2019;11:2162.
Misselwitz B, Butter M, Verbeke K, et al. Update on lactose malabsorption and intolerance: Pathogenesis, diagnosis and clinical management. Gut 2019;68:2080–91.
Campbell AK, Waud JP, Matthews SB. The molecular basis of lactose intolerance. Sci Prog 2009;92:241–87.
Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:738–46.
Vesa TH, Seppo LM, Marteau PR, et al. Role of irritable bowel syndrome in subjective lactose intolerance. Am J Clin Nutr 1998;67:710–5.
Yang J, Fox M, Cong Y, et al. Lactose intolerance in irritable bowel syndrome patients with diarrhoea: The roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity. Aliment Pharmacol Ther 2014;39:302–11.
Melchior C, Douard V, Coëffier M, et al. Fructose and irritable bowel syndrome. Nutr Res Rev 2020;33:235–43.
Biesiekierski JR. Fructose-induced symptoms beyond malabsorption in FGID. United European Gastroenterol J 2014;2:10–3.
Wilder-Smith CH, Olesen SS, Materna A, et al. Fermentable sugar ingestion, gas production, and gastrointestinal and central nervous system symptoms in patients with functional disorders. Gastroenterology 2018;155:1034–44.e6.
Wilder-Smith C, Lee SH, Olesen SS, et al. Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2021;33:e14150.
Major G, Pritchard S, Murray K, et al. Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome. Gastroenterology 2017;152:124–33.e2.
Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr 2012;55(Suppl 2):S7–13.
Cohen SA. The clinical consequences of sucrase-isomaltase deficiency. Mol Cell Pediatr 2016;3:5.
Chey WD, Cash B, Lembo A, et al. Congenital sucrase-isomaltase deficiency: What, when, and how? Gastroenterol Hepatol 2020;16:3–11.
Henström M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut 2018;67:263–70.
Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol 2018;16:1673–6.
Thingholm L, Rühlemann M, Wang J, et al. Sucrase-isomaltase 15Phe IBS risk variant in relation to dietary carbohydrates and faecal microbiota composition. Gut 2019;68:177–8.
Zheng T, Eswaran S, Photenhauer AL, et al. Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants. Gut 2020;69:397–8.
Foley A, Halmos EP, Husein DM, et al. Adult sucrase-isomaltase deficiency masquerading as IBS. Gut 2021:1237–38.
Drossman DA, Hasler WL. Rome IV-functional GI disorders: Disorders of gut-brain interaction. Gastroenterology 2016;150:1257–61.
Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013;108:707–17.
Staudacher HM, Irving PM, Lomer MC, et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014;11:256–66.
Simrén M. Diet as a therapy for irritable bowel syndrome: Progress at last. Gastroenterology 2014;146:10–2.
Marciani L, Cox EF, Hoad CL, et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010;138:469–77, 477.e1.
Dellschaft N, Hoad C, Marciani L, et al. Small bowel water content assessed by MRI in health and disease: A collation of single-centre studies. Aliment Pharmacol Ther 2022;55:327–38.
Lam C, Chaddock G, Marciani Laurea L, et al. Distinct abnormalities of small bowel and regional colonic volumes in subtypes of irritable bowel syndrome revealed by MRI. Am J Gastroenterol 2017;112:346–55.
Simrén M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018;15:589–605.
Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989;30:634–41.
Narducci F, Bassotti G, Granata MT, et al. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide. Dig Dis Sci 1986;31:241–6.
Sullivan MA, Cohen S, Snape WJ Jr. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978;298:878–83.
Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499–506.
Böhn L, Störsrud S, Törnblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108:634–41.
Enck P, Azpiroz F, Boeckxstaens G, et al. Functional dyspepsia. Nat Rev Dis Primers 2017;3:17081.
Wiley J, Tatum D, Keinath R, et al. Participation of gastric mechanoreceptors and intestinal chemoreceptors in the gastrocolonic response. Gastroenterology 1988;94:1144–9.
Wright SH, Snape WJ Jr, Battle W, et al. Effect of dietary components on gastrocolonic response. Am J Physiol 1980;238:G228–32.
Rao SS, Kavelock R, Beaty J, et al. Effects of fat and carbohydrate meals on colonic motor response. Gut 2000;46:205–11.
Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48:14–9.
Serra J, Salvioli B, Azpiroz F, et al. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002;123:700–6.
Simrén M, Törnblom H, Palsson OS, et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: Consistent findings from five different patient cohorts. Gut 2018;67:255–62.
Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001;48:20–7.
Simrén M, Abrahamsson H, Björnsson ES. Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: The role of bowel habit, sex, and psychologic factors. Clin Gastroenterol Hepatol 2007;5:201–8.
Khan A, Suarez MG, Murray JA. Nonceliac gluten and wheat sensitivity. Clin Gastroenterol Hepatol 2020;18:1913–22.e1.
Zevallos VF, Raker V, Tenzer S, et al. Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells. Gastroenterology 2017;152:1100–13.e12.
Uhde M, Caio G, De Giorgio R, et al. Subclass profile of IgG antibody response to gluten differentiates nonceliac gluten sensitivity from celiac disease. Gastroenterology 2020;159:1965–7.e2.
Pinto-Sanchez MI, Nardelli A, Borojevic R, et al. Gluten-free diet reduces symptoms, particularly diarrhea, in patients with irritable bowel syndrome and antigliadin IgG. Clin Gastroenterol Hepatol 2021;19:2343–52.e8.
Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014;147:1012–20.e4.
Fritscher-Ravens A, Pflaum T, Mösinger M, et al. Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Gastroenterology 2019;157:109–18.e5.
Kiesslich R, Adib-Tezer H, Teubner D, et al. Food allergy sensitivity test (fast) with endomicroscopy of the duodenum enables tailored exclusion diet in patients with irritable bowel syndrome. Gastrointest Endosc 2021;2021:AB207.
Bojarski C, Tangermann P, Barmeyer C, et al. Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. Gut 2021:1–10. doi:10.1136/gutjnl-2021-325181.
doi: 10.1136/gutjnl-2021-325181
Van den Houte K, Carbone F, Toth J, et al. Symptoms and duodenal mucosal integrity are improved by A dietary intervention in functional dyspepsia. UEG J 2021;9:S-96.
McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut 2017;66:1241–51.
Schol J, Roelants E, Van Den Houte K, et al. Improvement of functional dyspepsia symptoms by the six food elimination diet. Neurogastroenterol Motil 2021;33:28–9.
Schol J, Balsiger L, Tóth J, et al. Role of atypical food allergies in functional dyspepsia: Evaluation by six-food elimination diet and confocal laser endomicroscopy food allergy testing (Abstract for DDW 2022 and also Belgian Week of Gastroenterology 2022). Gastroenterology 2021.
Nojkov B, Zhou SY, Dolan RD, et al. Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and “ex vivo” mucosa analysis. Am J Gastroenterol 2020;115:1891–901.
Tack J, Schol J, Van den Houte K, et al. Paradigm shift: Functional dyspepsia-A “leaky gut” disorder? Am J Gastroenterol 2021;116:274–5.
Aguilera-Lizarraga J, Florens MV, Viola MF, et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature 2021;590:151–6.
Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut 2004;53:1459–64.
Ligaarden SC, Lydersen S, Farup PG. IgG and IgG4 antibodies in subjects with irritable bowel syndrome: A case control study in the general population. BMC Gastroenterol 2012;12:166.
Aydinlar EI, Dikmen PY, Tiftikci A, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache 2013;53:514–25.
Butuci M, Gebremeskel S, Peterson KA, et al. Activated mast cells and eosinophils are associated with increased inflammatory mediators in mucosal biopsies from patients with chronic gastrointestinal symptoms. Gastroenterology 2021;160:S-251–2.
Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.
Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26–37.
Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636–47.
Bischoff SC, Mayer J, Wedemeyer J, et al. Colonoscopic allergen provocation (COLAP): A new diagnostic approach for gastrointestinal food allergy. Gut 1997;40:745–53.
Rondón C, Fernández J, López S, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol 2009;124:1005–11.e1.
Lopez-Lopez C, Jaramillo-Polanco J, Yu Y, et al. Food antigen-stress interaction leads to increase pain signaling in ileum and colon via STAT6 in an IBS model. J Can Assoc Gastroenterol 2021;4(S1):11–2.
Tuck CJ, Vanner SJ. Dietary therapies for functional bowel symptoms: Recent advances, challenges, and future directions. Neurogastroenterol Motil 2018;30.
Zhou SY, Gillilland M III, Wu X, et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J Clin Invest 2018;128:267–80.
Singh P, Grabauskas G, Zhou SY, et al. High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight 2021;6:e146529.
Tuck C, Abu Omar A, Lopez-Lopez C, et al. A longitudinal study of FODMAP intake on the metabolome and pain signaling in IBS patients. Neurogastroenterol Motil 2020;32:128.
De Palma G, Shimbori C, Reed DE, et al. Microbial histamine induces visceral hyperalgesia through H4 receptor dependent mechanisms. Sci Transl Med 2022, in press.
Gecse K, Róka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591–9.
Gao K, Mu CL, Farzi A, et al. Tryptophan metabolism: A link between the gut microbiota and brain. Adv Nutr 2020;11:709–23.
Bhattarai Y, Williams BB, Battaglioli EJ, et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe 2018;23:775–85.e5.
Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018;23:716–24.
Bennet SMP, Bohn L, Storsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 2018;67:872–81.
Tap J, Störsrud S, Le Nevé B, et al. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. Microbiome 2021;9:74.
Chumpitazi BP, Cope JL, Hollister EB, et al. Randomised clinical trial: Gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 2015;42:418–27.
Mayer EA. Gut feelings: The emerging biology of gut-brain communication. Nat Rev Neurosci 2011;12:453–66.
Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012;10:735–42.
Ly HG, Dupont P, Van Laere K, et al. Differential brain responses to gradual intragastric nutrient infusion and gastric balloon distension: A role for gut peptides? Neuroimage 2017;144:101–12.
Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013;108:1382–91.
Vijayvargiya P, Camilleri M, Chedid V, et al. Effects of promotility agents on gastric emptying and symptoms: A systematic review and meta-analysis. Gastroenterology 2019;156:1650–60.